‚ЂƂè‚Å”Y‚Þ‘O‚ɍè’JˆãŽtiˆãŠw”ŽŽmj‚Ö–âf‘Š’k‚ð‚Ç‚¤‚¼B‚¨\‚µž‚݂́˃Rƒ`ƒ‰

ƒŠƒEƒ}ƒ`‚Ì•W€Ž¡—Ái‚P‚Qj

ŠÖßƒŠƒEƒ}ƒ`‚ɑ΂·‚鐶•¨Šw“I»ÜŽs”̌㒲¸

2003 ”N‚ÉinfliximabA2005”N‚Éetanercept‚ª“ú–{‚ÅŽg—p‰Â”\‚É‚È‚èŽs”ÌŒã‘S—á’²¸‚ªs‚í‚ꂽB2008”N‚É‚ÍtocilizumabA adalimubmab‚ª“ú–{‚ÅŽg—p‰Â”\‚ƂȂ茻ÝŽs”ÌŒã‘S—á’²¸’†‚Å‚ ‚éB“Á‚ɍ׋ې«”x‰ŠAƒJƒŠƒj”x‰ŠAŒ‹Šj‚É‹C‚ð‚‚¯‚È‚¯‚ê‚΂Ȃç‚È‚¢BƒJƒŠƒj”x‰Š‚Æ Œ‹Šj‚Í“Š–ò—\–h‚ª‰Â”\‚Ȃ̂ō‚ƒŠƒXƒNŠ³ŽÒ‚Å‚Í—\–h“Š–ò‚ðl—¶‚µ‚½‚Ù‚¤‚ª‚æ‚¢‚ÆŽv‚í‚ê‚éB

“ú–{‚Å‚ÌinfliximabŽs”ÌŒã5000—á‚Ì’²¸‚É‚¨‚¯‚éd“Ä‚È—LŠQŽ–Û‚́A308—á 6.2%‚Å‚ ‚Á‚½B

×‹Û«”x‰Ši108—á 2.2“j’j«A‚—îAis‚µ‚½RAA”xŽ¾Š³‡•¹Š³ŽÒ‚ȂǂŃŠƒXƒN‚ª2”{’ö“xã¸‚·‚é

ŠÔŽ¿«”x‰Ši25—á 0.‚T“j

ƒJƒŠƒj”x‰Ši22—á 0.4“j65ÎˆÈãAPSL 6mg/“úˆÈãA”xŽ¾Š³‚̍‡•¹—á‚ŃŠƒXƒN‚ª2-3”{ã¸‚·‚éB2ˆöŽqˆÈã•Û—L‚È‚çST‡Ü‚É‚æ‚é—\–h‚ðl—¶BŽ€–S—¦27“‚Ì•ñ‚ ‚èB

Œ‹Šji14—á 0.3“jƒc”½‹­—z«‚ȂljߋŽ‚ÌŠ´õŠù‰‚ª‹^‚í‚ê‚éê‡INH‚Ì—\–h“Š—^‚ðl—¶

“ú–{‚Å‚ÌetanerceptŽs”ÌŒã7091—á‚Ì’²¸‚É‚¨‚¯‚éd“Ä‚È—LŠQŽ–Û‚́A403—á 5.7“‚Å‚ ‚Á‚½B

ŒÄ‹zŠúŠ´õÇ 367—á 5.56“i×‹Û«”x‰Š96—á 1.35“, ƒJƒŠƒj”x‰Š 16—á 0.23“, Œ‹Šj 10—á 0.14“j

ŠÔŽ¿«”x‰Š 44—á 0.62“

”畆“î•”‘gDŠ´õÇ 40—á 0.56“

‘SgáŠQA“Š—^‹ÇŠ—l‘Ô 39—á 0.18“

o“T
**Takeuchi T et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 67(2):189-94 2008. **Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 52(6):1481-4 2007. **Fujieda Y et al •ªŽqƒŠƒEƒ}ƒ`Ž¡—à 1(2)14-17 2008. **Enbrel.jp

ƒŠƒEƒ}ƒ`‚Ì•W€Ž¡—Ái‚Pj i‚Qji‚Rji‚Sji‚Tji‚Uji‚Vji‚Wji‚Xji‚P‚Oji‚P‚Pji‚P‚Qji‚P‚Rji‚P‚Sji‚P‚Tji‚P‚Uji‚P‚Vj
ŠÖßƒŠƒEƒ}ƒ`‘ŠúŽ¡—Â̏d—v«
TNF‘jŠQ–ò–³Œø‚̊֐߃ŠƒEƒ}ƒ`  ‰p‘—§—Տ°•]‰¿Œ¤‹†ŠiNICEj‚ªŽ¡—ÃKƒCƒ_ƒ“ƒX‘ˆÄ‚ð”­•\

ŽŸƒy[ƒW‚ցFè’JŒ¤‹†Š‚̃ŠƒEƒ}ƒ`Ž¡—Ð헪

ƒy[ƒWƒgƒbƒv‚Ö

  • è’JˆãŽtiˆãŠw”ŽŽmj‚Ì–âf‘Š’k
  • ‚²‘Š’k“à—e‚ðŒµ‘I‚µ‘Il‚̏ãA‚²•Ô“š‚³‚¹‚Ä’¸‚«‚Ü‚·B

‚¨\ž‚Ý‚Í‚±‚¿‚çË